Clinical Epidemiology
Immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine in people aged 60 years and above
Ma Qianli, Zhang Min, Liu Lijun, Zhou Yan, Yuan Wei, Yang Mei, Liu Shaoxiang, Luo Linyun, Chen Haiping, Xiao Yanhui, Qi Qi, Yang Xiaoming
Published 2023-07-10
Cite as Chin J Epidemiol, 2023, 44(7): 1119-1125. DOI: 10.3760/cma.j.cn112338-20221130-01019
Abstract
ObjectiveTo evaluate the immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine (PPV23) in elderly people aged ≥60 years.
MethodsThe elderly aged ≥60 years with 1 dose of PPV23 vaccination were selected as revaccination group and those without history of pneumococcal vaccine immunization were selected as the first vaccination group. One dose of PPV23 was administered to both groups, and the first blood samples were collected before vaccination while the second blood samples were collected on day 28-40 after vaccination. ELISA was used to detect the concentrations of anti-specific serotype Streptococcus pneumoniae podocyte polysaccharide immunoglobulin G, and the safety of the vaccination was evaluated after 30 days.
ResultsThe geometric mean concentration (GMC) of antibody to 23 serotypes before the vaccination (0.73-13.73 μg/ml) was higher in revaccination group than in the first vaccination group (0.39-7.53 μg/ml), the GMC after the vaccination (1.42-31.65 μg/ml) was higher than that before the vaccination (0.73-13.73 μg/ml) in the revaccination group, and the GMC after the vaccination (1.62-43.76 μg/ml) was higher than that before the vaccination (0.39-7.53 μg/ml) in the first vaccination group; the geometric mean growth multiple in revaccination group (2.16-3.60) was lower than that in the first vaccination group (3.86-16.13); The mean 2-fold antibody growth rate was lower in revaccination group (53.68%, 95%CI: 52.30%-55.06%) than in the first vaccination group (93.16%, 95%CI: 92.18%- 94.15%), all differences were significant (P<0.001). After the vaccination, 13 serotypes of GMC were higher in the first vaccination group than in revaccination group (P<0.001), the differences were not significant for 10 serotypes of GMC (P>0.05). The incidence of local adverse reaction was 19.20% and 13.27% in revaccination group and the first vaccination group, respectively (P=0.174).
ConclusionsThe antibody level in ≥60 years people who received one dose of PPV23 after a 5-year interval was still higher than that in unvaccinated people. The antibody level decreased after 5 years of the first vaccination, and the antibody level could be rapidly increased by one more dose vaccination, but the overall immune response was lower than that of the first vaccination; revaccination with PPV23 has a good safety.
Key words:
Pneumococcal vaccines; Revaccination; Immunogenicity; Safety
Contributor Information
Ma Qianli
Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610041, China
Zhang Min
China National Biotech Group Company Limited, Beijing 100024, China
Liu Lijun
Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610041, China
Zhou Yan
Xinjin District Center for Disease Control and Prevention, Chengdu 611430, China
Yuan Wei
Sichuan Tianfu New District Public Health Center, Chengdu 610213, China
Yang Mei
Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610041, China
Liu Shaoxiang
Chengdu Institute of Biological Products Co. Ltd, Sichuan Vaccine Engineering Technology Research Center, Chengdu 610023, China
Luo Linyun
China National Biotech Group Company Limited, Beijing 100024, China
Chen Haiping
China National Biotech Group Company Limited, Beijing 100024, China
Xiao Yanhui
China National Biotech Group Company Limited, Beijing 100024, China
Qi Qi
Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610041, China
Yang Xiaoming
China National Biotech Group Company Limited, Beijing 100024, China
